Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.
Core Laboratories Stock Up 0.4 %
NYSE:CLB traded up $0.07 during trading on Friday, hitting $16.35. The stock had a trading volume of 567,114 shares, compared to its average volume of 464,964. Core Laboratories has a 12 month low of $15.21 and a 12 month high of $35.83. The company has a market capitalization of $757.50 million, a PE ratio of 86.06, a P/E/G ratio of 0.71 and a beta of 2.59. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.53 and a current ratio of 2.08. The company's 50-day moving average price is $20.76 and its two-hundred day moving average price is $25.66.
Core Laboratories (NYSE:CLB - Get Rating) last posted its earnings results on Wednesday, July 27th. The oil and gas company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.14 by ($0.02). Core Laboratories had a return on equity of 16.12% and a net margin of 1.82%. The business had revenue of $120.90 million for the quarter, compared to analyst estimates of $121.35 million. During the same period in the previous year, the firm posted $0.18 earnings per share. The firm's revenue was up 1.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Core Laboratories will post 0.56 EPS for the current year.
Core Laboratories Cuts Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 29th. Investors of record on Monday, August 8th will be given a dividend of $0.01 per share. The ex-dividend date is Friday, August 5th. This represents a $0.04 annualized dividend and a dividend yield of 0.24%. Core Laboratories's dividend payout ratio is currently 21.05%.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Core Laboratories from $22.00 to $20.00 and set an "equal weight" rating for the company in a research report on Monday, August 1st. StockNews.com raised Core Laboratories from a "sell" rating to a "hold" rating in a research report on Wednesday, May 11th. Stifel Nicolaus reduced their target price on Core Laboratories from $26.00 to $20.00 in a research report on Tuesday, July 26th. Finally, Piper Sandler cut Core Laboratories from a "neutral" rating to an "underweight" rating and lifted their price objective for the company from $19.50 to $21.30 in a report on Monday, April 18th.